Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.135 EUR | +1.34% | +8.10% | +1.34% |
Apr. 19 | Theranexus: share price rises following promising trial results | CF |
Mar. 11 | Theranexus: CEO takes over as Chairman of the Board | CF |
Business Summary
Theranexus has a unique platform for the identification and characterization of innovative therapy drug candidates in rare neurological disorders and a first drug candidate in clinical development for Batten disease.
Number of employees: 19
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 13-03-18 | |
Founder | - | 13-03-18 | |
Director of Finance/CFO | - | 16-12-31 | |
Marie Sebille
CTO | Chief Tech/Sci/R&D Officer | - | 21-10-18 |
Human Resources Officer | - | 17-12-31 | |
Julien Veys
PRN | Corporate Officer/Principal | - | 15-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jérôme Martinez
BRD | Director/Board Member | 63 | 18-12-12 |
Director/Board Member | 50 | 17-09-25 | |
Founder | - | 13-03-18 | |
Chief Executive Officer | - | 13-03-18 | |
Director/Board Member | 51 | - | |
Eric Doulat
BRD | Director/Board Member | - | 19-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,346,213 | 4,220,699 ( 78.95 %) | 0 | 78.95 % |
Company contact information
Theranexus SA
Pépinière Laennec 60, avenue Rockefeller
69008, Lyon
+33 1 88 89 70 31
http://www.theranexus.comSector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.34% | 9.31M | |
-2.31% | 103B | |
+0.56% | 95.71B | |
+1.69% | 22.02B | |
-17.37% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.85% | 15.52B | |
+3.21% | 13.86B | |
+33.54% | 12.04B |
- Stock Market
- Equities
- ALTHX Stock
- Company Theranexus